Swiss National Bank Acquires 15,200 Shares of IDEXX Laboratories, Inc. $IDXX

Swiss National Bank grew its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.9% in the first quarter, HoldingsChannel reports. The fund owned 234,380 shares of the company’s stock after acquiring an additional 15,200 shares during the period. Swiss National Bank’s holdings in IDEXX Laboratories were worth $131,696,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of IDXX. Empowered Funds LLC boosted its holdings in IDEXX Laboratories by 6.6% during the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock worth $646,000 after buying an additional 95 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at about $265,000. Jump Financial LLC raised its position in shares of IDEXX Laboratories by 1,006.4% in the 2nd quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock valued at $2,967,000 after acquiring an additional 5,032 shares during the period. Cary Street Partners Financial LLC acquired a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at approximately $164,000. Finally, Sei Investments Co. boosted its stake in IDEXX Laboratories by 218.7% during the 2nd quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock worth $64,678,000 after acquiring an additional 82,755 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $563.81 on Tuesday. The company has a market cap of $44.47 billion, a PE ratio of 41.52, a price-to-earnings-growth ratio of 3.10 and a beta of 1.55. The firm has a 50-day moving average of $555.13 and a 200-day moving average of $598.49. IDEXX Laboratories, Inc. has a one year low of $513.02 and a one year high of $769.98. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period in the previous year, the firm earned $2.91 EPS. The firm’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on IDXX shares. Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. UBS Group reduced their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Stifel Nicolaus decreased their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Finally, Citigroup assumed coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target for the company. Six investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.